Nektar Q1 net loss $50.9M, cash $220.7M; Phase 2 data expected June

NEKTAR THERAPEUTICS

2025-Q1 EPS reported -$0.24 revenue$10,460,000

Cash & marketable securities $220.7M, expected to fund operations into Q4 2026.
Revenue $10.5M, down from $21.6M YoY due to sale of Huntsville facility.
Net loss $50.9M ($0.24/share) vs $36.8M ($0.19) in Q1 2024; non-GAAP loss $46.4M.
Topline Phase 2 data for rezpegaldesleukin in atopic dermatitis expected June 2025.
FDA granted Fast Track designation for rezpegaldesleukin in atopic dermatitis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.